14 results about "Subtilisin" patented technology

Disclosed herein is one or more subtilisin variant, nucleic acid encoding same, and compositions and methods related to the production and use thereof, including one or more subtilisin variant that has improved stability compared to one or more reference subtilisin.

The present invention relates to a dual-targeting siRNA agent comprising two distinct siRNAs targeting two different genes or their pharmaceutically acceptable salts, wherein the two distinct siRNAs or their salts are linked by a pharmaceutically acceptable ligand. The siRNA is a dsRNA composed of a sense strand and an antisense strand, and the two different genes are selected from a group consisting of angiotensinogen (AGT), proprotein convertase subtilisin / kexin type 9 (PCSK9), and human angiopoietin-like protein 3 (ANGPTL3). The present invention provides the application of the dual-targeting siRNA agent in the preparation of drugs for preventing or treating diseases associated with hypertension and / or dyslipidemia. The dual-targeting siRNA agent described in the present invention can effectively inhibit the expression of two target genes simultaneously in vivo, offering the advantages of strong non-antagonistic activity and high safety. The present invention also provides the siRNAs targeting corresponding genes for the aforementioned dual-targeting siRNA agent and their use for preventing or treating diseases associated with hypertension and / or dyslipidemia.

Disclosed are, inter alia, combinations comprising a first antisense (e.g., first double stranded RNAi (dsRNAi)) agent for inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, and a second antisense agent (e.g., second dsRNAi agent) for inhibiting expression of lipoprotein (a) (Lp(a)); pharmaceutical compositions including the same, and methods of treatment using the same.

A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having α2-3-linked N-glycolylneuraminic acid and glycans having α2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having α2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having α2-3-linked N-glycolylneuraminic acid.

This invention relates to compounds of Formula I and their isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, hydrates, prodrugs, and polymorphs. The compounds of Formula I can be used as inhibitors of proprotein convertase subtilisin 9 (PCSK9), effectively inhibiting PCSK9 activity and reducing the concentration of low-density lipoprotein cholesterol in plasma, and have good application prospects in the preparation of drugs for the treatment or prevention of cardiovascular diseases.

Disclosed herein is one or more subtilisin variant, nucleic acid encoding same, and compositions and methods related to the production and use thereof, including one or more subtilisin variant that has improved stability and / or soil removal compared to one or more reference subtilisin.

Subtilase variants having improved stability are provided, detergent compositions comprising the variants, the use of the variants and detergent compositions in a cleaning method, such as washing clothes or cleaning hard surfaces, such as washing dishes, and methods for producing the variants.

Disclosed are, inter alia, combinations comprising a first antisense (e.g., first double stranded RNAi (dsRNAi)) agent for inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, and a second antisense agent (e.g., second dsRNAi agent) for inhibiting expression of angiotensinogen (AGT); pharmaceutical compositions including the same, and methods of treatment using the same.

The application discloses a polynucleotide sequence for simultaneously reducing blood fat and blood pressure and application thereof. Cell and mouse experiments show that the application can significantly inhibit the expression levels of multiple blood fat and blood pressure molecular targets such as proprotein convertase subtilisin / kexin type 9 (PCSK9), angiotensinogen (AGT) and beta-hydroxy-beta-methylglutaryl-coenzyme a reductase (HMGCR), thereby reducing the blood fat and blood pressure levels of a related disease model mouse. The application is expected to be applied to treating related cardiovascular and cerebrovascular diseases complicated with high blood fat and high blood pressure symptoms.

Aspects of the technology relate to a composition comprising: (i) a first RNAi agent that targets Proprotein convertase subtilisin / kexin type 9 (PCSK9) and a second RNAi agent that targets angiotensinogen (AGT); (ii) a first RNAi agent that targets PCSK9 and a third RNAi agent that targets Apolipoprotein A (LPA); (iii) a second RNAi agent that targets AGT and a third RNAI agent that targets LPA, or (iv) a first RNAi agent that targets PCSK9, a second RNAi agent that targets AGT, and the third RNAi agent that targets LPA.

Provided are a small interfering RNA (siRNA) used to inhibit the expression of proprotein convertase subtilisin / kexin type 9 (PCSK9) in a cell, a vector comprising nucleotides encoding same, and a cell, as well as a method using the siRNA, the vector or the cell for the treatment of diseases or symptoms associated with the expression of PCSK9 in a subject.

The present application belongs to the technical field of feed additive, and particularly relates to a feed additive for increasing the content of branched-chain fatty acids in milk and a preparation method thereof.The feed additive for increasing the content of branched-chain fatty acids in milk comprises the following raw materials in parts by weight: 1-4 parts of leucine, 1-4 parts of isoleucine, 1-4 parts of valine, 1-2.5 parts of Prinsepia uniflora extract and 0.3-0.6 parts of sodium subtilisin lipopeptide.The feed additive for increasing the content of branched-chain fatty acids in milk is prepared by using different types of amino acids and Prinsepia uniflora extract and sodium subtilisin lipopeptide in combination, and can significantly increase the content of branched-chain fatty acids in milk, improve the quality of milk and the milk production performance of dairy cows after being used in the daily ration of dairy cows.The feed additive is safe in composition and has no toxic side effects.

The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin / kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

The application belongs to the technical field of biotechnology and functional food technology, and particularly relates to whey protein enzymatic hydrolysate for promoting high-efficiency digestion and absorption of branched-chain amino acids of the elderly, and a preparation method and application thereof. The method uses whey protein as raw material, adopts at least one of trypsin, alkaline protease and subtilisin for directional enzymolysis, and introduces an alkali-heat induction treatment step. The method successfully prepares small-size, uniformly-distributed enzymatic hydrolysate particles, and can efficiently retain branched-chain amino acids. In vitro simulation of an elderly digestion model coupled with a Caco-2 cell absorption model verifies that the protein digestion rate is significantly higher than that of unenzymolysed whey protein, and the Caco-2 cell model shows that the BCAA absorption rate is obviously improved. The application effectively solves the problems of low absorption rate and unstable system of traditional whey protein peptides in the digestive environment of the elderly, and the prepared enzymatic hydrolysate can be used for developing functional food and health products such as prevention of sarcopenia of the elderly or sports nutrition supplements.